Video Discussion: The Growing Importance of Sustainability in Pharma
A question of sustainability: how can pharma companies up their environmental Game? Experts discuss in our video roundtable.
Stephanie Sutton | | Video
Sustainability is becoming an increasing important topic for the entire world and everyone – and every industry – must play their part. What does this mean for pharma? I spoke with four experts from different corners of the industry to find out their thoughts on the importance of sustainability, protecting the planet, and what action companies can take – both small and large – to help make a difference.
Brian Peutherer, HSE Director, Sterling Pharma Solutions
Brian Peutherer is responsible for the operational and regulatory aspects of health, safety and environmental performance at Sterling’s Dudley, UK site. This includes overseeing the commercial biological treatment facility and waste management operations, and the facilities management team. He has over 20 years’ experience across process design engineering and process safety for speciality chemicals, having previously held positions at ChiRex, Pfizer, Piramal Healthcare and Aesica Pharmaceuticals.
Katie Murray, Technical Director, Centre for Process Innovation’s Medicines Manufacturing Innovation Centre (MMIC)
Katie is a chemical engineer with over 25 years’ experience in the pharmaceutical industry. She started her career in process development and scale-up roles with both Merck and Co in the US and AstraZeneca in the UK, before moving to technical leadership roles in the deployment of technology into large capital projects, also at AstraZeneca. Her expertise covers both drug substance and drug product development and manufacture.
Dr. Jnanadeva Bhat, Head – Formulation R&D (Pharma & Nutra), ACG Group
Jnanadeva Bhat has been associated with the pharmaceutical industry for more than two and a half decades. As a product formulator, he has worked on various dosage forms that include tablets, soft gelatin and hard capsules, injectables and lyophilized formulations. At ACG, he heads the formulation R&D lab where he primarily leads new product development projects and customer interface.
Peter Soelkner, Managing Director, Vetter Pharma-Fertigung GmbH & Co KG
Peter Soelkner has been in his current role since June 2008. In 2009, he was also appointed Managing Director of Vetter Pharma International GmbH, the company’s marketing and sales organization. Soelkner graduated from the University of Dortmund, Germany, in 1992 with a degree in chemical engineering and earned an MBA from Columbia University, New York, in 2001. Before joining Vetter, he held positions in Germany and North America at Sartorius AG and Sartorius North America Inc in R&D, marketing, key account management, and general management roles. At Vetter, from 2003 to 2007, Soelkner managed the company’s key account program and global end-to-end supply chain. He left the company for a year to serve as Vice President of global key account management at Sartorius Stedim Biotech (USA), before returning to Vetter in 2008.